112 related articles for article (PubMed ID: 15247985)
1. Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?
Contreras DN; Cobos E; Lox C
Clin Appl Thromb Hemost; 2004 Jul; 10(3):271-6. PubMed ID: 15247985
[TBL] [Abstract][Full Text] [Related]
2. The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).
Jumper C; Cobos E; Lox C
Anticancer Res; 2002; 22(4):2073-6. PubMed ID: 12174885
[TBL] [Abstract][Full Text] [Related]
3. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the circulating fraction of the HER-2/neu oncogene in patients with cervical cancer.
Contreras DN; Cobos E; Lox CD
Eur J Gynaecol Oncol; 2002; 23(6):491-5. PubMed ID: 12556089
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions.
Daneri-Navarro A; Macias-Lopez G; Oceguera-Villanueva A; Del Toro-Arreola S; Bravo-Cuellar A; Perez-Montfort R; Orbach-Arbouys S
Eur J Cancer; 1998 Mar; 34(4):566-9. PubMed ID: 9713310
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus.
Sugimura M; Kobayashi H; Kanayama N; Terao T
Gynecol Oncol; 1992 Sep; 46(3):330-6. PubMed ID: 1526511
[TBL] [Abstract][Full Text] [Related]
7. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Kobayashi H; Fujishiro S; Terao T
Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients.
Abendstein B; Daxenbichler G; Windbichler G; Zeimet AG; Geurts A; Sweep F; Marth C
Anticancer Res; 2000; 20(1B):569-72. PubMed ID: 10769727
[TBL] [Abstract][Full Text] [Related]
10. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Koelbl H; Kirchheimer JC; Tatra G; Christ G; Binder BR
Obstet Gynecol; 1988 Aug; 72(2):252-6. PubMed ID: 3134631
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
13. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of HER-2/neu oncogene in cervical cancer.
Ndubisi B; Sanz S; Lu L; Podczaski E; Benrubi G; Masood S
Ann Clin Lab Sci; 1997; 27(6):396-401. PubMed ID: 9433536
[TBL] [Abstract][Full Text] [Related]
15. [Effect of genistein on expression of angiogenesis related factors in HER-2/neu-overexpressing breast cancer cells].
Yu XP; Mi MT; Zhu JD
Shi Yan Sheng Wu Xue Bao; 2004 Jun; 37(3):251-3. PubMed ID: 15323430
[TBL] [Abstract][Full Text] [Related]
16. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
17. [Urokinase-type plasminogen activator as a predictor for lymph nodes metastasis of uterine cervical cancer].
Fujishiro S; Kobayashi H; Terao T
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Feb; 46(2):129-36. PubMed ID: 8126385
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer.
Cobos E; Jumper C; Lox C
Clin Appl Thromb Hemost; 2003 Jul; 9(3):241-6. PubMed ID: 14507113
[TBL] [Abstract][Full Text] [Related]
19. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
20. Serum her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer.
Goksel G; Taneli F; Uslu R; Ulman C; Dinc G; Coskun T; Kandiloglu AR
J Int Med Res; 2007; 35(2):165-72. PubMed ID: 17542404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
